Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer

NCT06869226 is registered in ClinicalTrials.gov with Peking University Cancer Hospital & Institute as lead sponsor.

NCT NCT06869226
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06869226 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer
Lead sponsor
Peking University Cancer Hospital & Institute
Phase
Phase 2
Overall status
Recruiting
Start date
April 30, 2025
Completion date
December 31, 2029
Enrollment
283 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer